Structural aspects of the p53 protein in relation to gene evolution: A second look

Journal of Molecular Biology

Volumn 260, Issue 5, 1996, Pages 623-637

  Soussi, Thierry ^a   May, Pierre ^b  

^a INSERM   (France)

^b Lab de Cancerogenese Moleculaire   (France)

Author keywords

Cell cycle checkpoint; Conformation flexibility; DNA damage recognition; p53 tumor suppressor gene; Transcription factor

Indexed keywords

PROTEIN P53;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; EVOLUTION; GENE STRUCTURE; IMMUNOGENICITY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 0030564943     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1996.0425     Document Type: Review

References (145)

1. Addison, C., Jenkins, J. R. & Sturzbecher, H. W. (1990). The p53 nuclear localisation signal is structurally linked to a p34Cdc2 kinase motif. Oncogene, 5, 423-426.
2. Albor, A., Laborda, J. & Notario, V. (1994). Cloning the Syrian hamster p53 gene: structural and functional characterization of the upstream promoter region. Cancer Res. Mol. Carinog. 11, 176-183.
3. Arai, N., Nomura, D., Yokota, K., Wolf, D., Brill, E., Shohat, O. & Rotter, V. (1986). Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6, 3232-3239.
4. Bargonetti, J., Manfredi, J. J., Chen, X. B., Marshak, D. R. & Prives, C. (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53-protein. Gene Dev. 7, 2565-2574.
5. Bayle, J. H., Elenbaas, B. & Levine, A. J. (1995). The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad. Sci. USA, 92, 5729-5733.
6. Beenken, S. W., Karsenty, G., Raycroft, L. & Lozano, G. (1991). An intron binding protein is required for transformation ability of p53. Nucl. Acids Res. 19, 4747-4752.
7. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A. & Holmberg, L. (1995). Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1, 1029-1034.
8. Bienz, B., Zakut-Houri, R., Givol, D. & Oren, M. (1984). Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J. 3, 2179-2183.
9. Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C. & Beach, D. (1990). Human p53 is phosphorylated by P60-Cdc2 and cyclin-B-Cdc2. Proc. Natl Acad. Sci. USA, 87, 4766-4770.
10. Bischoff, J. R., Casso, D. & Beach, D. (1992). Human-p53 inhibits growth in schizosaccharomyces-pombe. Mol. Cell. Biol. 12, 1405-1411.
11. Braithwaite, A. W. & Jenkins, J. R. (1989). Ability of p53 and the adenovirus E1b 58-kilodalton protein to form a complex is determined by p53. J. Virol. 63, 1792-1799.
12. Buckbinder, L., Talbott, R., Velascomiguel, S., Takenaka, I., Faha, B., Seizinger, B. R. & Kley, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 377, 646-649.
13. Caron de Fromentel, C. & Soussi, T. (1992). TP53 Tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer, 4, 1-15.
14. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K. & May, P. (1987). Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39, 185-189.
15. Caron de Fromentel, C., Pakdel, F., Chapus, A., Baney, C., May, P. & Soussi, T. (1992). Rainbow trout p53-cDNA cloning and biochemical characterization. Gene, 112, 241-245.
16. Chen, J. D., Marechal, V. & Levine, A. J. (1993). Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13, 4107-4114.
17. Cho, Y. J., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science, 265, 346-355.
18. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E. & Gronenborn, A. M. (1994). High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386-391.
19. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E. & Gronenborn, A. M. (1995). Interhelical angles in the solution structure of the oligomerization domain of p53 (vol 265, p. 386, 1994). Science, 267, 1515-1516.
20. Cox, L. S. & Lane, D. P. (1995). Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays, 17, 501-508.
21. Crawford, L. (1983). The 53,000-dalton cellular protein and its role in transformation. Int. Rev. Expt. Pathol. 25, 1-50.
22. Crawford, L. V., Pim, D. C. & Bulbrook, R. D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30, 403-408.
23. Crook, T., Marston, N. J., Sara, E. A. & Vousden, K. H. (1994). Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79, 817-827.
24. Dang, C. V. & Lee, W. M. F. (1989). Nuclear and nucleolar targeting sequences of C-Erb-A, C-Myb, N-myc, p53, Hsp70, and HIV TAT proteins. J. Biol. Chem. 264, 18019-18023.
25. Dowell, S. P., Wilson, P. O. G., Derias, N. W., Lane, D. P. & Hall, P. A. (1994). Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 54, 2914-2918.
26. Dutta, A., Ruppert, J. M., Aster, J. C. & Winchester, E. (1993). Inhibition of DNA replication factor RPA by p53. Nature, 365, 79-82.
27. El-Deiry, W. S., Kern, S. E., Pientenpol, J. A., Kinzler, K. W. & Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nature Genet. 1, 45-49.
28. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
29. Elkind, N. B., Goldfinger, N. & Rotter, V. (1995). Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)(n) repeats. Oncogene, 11, 841-851.
30. Elledge, R. M. & Lee, W. H. (1995). Life and death by p53. BioEssays, 17, 923-930.
31. Feitelson, M. A., Zhu, M., Duan, L. X. & London, W. T. (1993). Hepatitis-B x-antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8, 1109-1117.
32. Fields, S. & Jang, S. K. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science, 249, 1046-1049.
33. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M. & Levine, A. J. (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half life. J. Virol. 8, 531-539.
34. Fiscella, M., Ullrich, S. J., Zambrano, N., Shields, M. T., Lin, D., Leesmiller, S. P., Andersen, C. W., Mercer, W. E. & Appella, E. (1993). Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene, 8, 1519-1528.
35. Flaman, J. M., Waridel, F., Estreicher, A., Vannier, A., Limacher, J. M., Gilbert, D., Iggo, R. & Frebourg, T. (1996). The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene, 12, 813-818.
36. Foord, O. S., Bhattacharya, P., Reich, Z. & Rotter, V. (1991). A DNA binding domain is contained in the C-terminus of wild-type p53-protein. Nucl. Acids Res. 19, 5191-5198.
37. Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W. & Harris, C. C. (1995). Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.
38. Fukuda, I. & Ogawa, K. (1992). Alternatively-spliced p53 mRNA in the FAA-HTC1 rat hepatoma cell line without the splice mutation. Cell Struct. Funct. 17, 427-432.
39. Gannon, J. V., Greaves, R., Iggo, R. & Lane, D. P. (1990). Activating mutations in p53 produce a common conformational effect - A monoclonal antibody specific for the mutant form. EMBO J. 9, 1595-1602.
40. Goh, H. S., Yao, J. & Smith, D. R. (1995). p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55, 5217-5221.
41. Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
42. Hainaut, P. & Milner, J. (1993a). Redox modulation of p53 conformation and Sequence-Specific DNA binding in vitro. Cancer Res. 53, 4469-4473.
43. Hainaut, P. & Milner, J. (1993b). A structural role for metal ions in the wild-type conformation of the tumor suppressor protein-p53. Cancer Res. 53, 1739-1742.
44. Halazonetis, T. D., Davis, L. J. & Kandil, A. N. (1993). Wild-type p53 adopts a mutant-like conformation when bound to DNA. EMBO J. 12, 1021-1028.
45. Harlow, E., Williamson, N. M., Ralston, R., Helfman, D. M. & Adams, T. E. (1985). Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol. Cell. Biol. 5, 1601-1610.
46. Herrmann, C. P. E., Kraiss, S. & Montenarh, M. (1991). Association of case in kinase-11 with immunopurified p53. Oncogene, 6, 877-884.
47. Hinds, P., Finlay, C. & Levine, A. J. (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63, 739-746.
48. Horikoshi, N., Usheva, A., Chen, J. D., Levine, A. J., Weinmann, R. & Shenk, T. (1995). Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15, 227-234.
49. Hulla, J. E. (1992). The rat Genome contains a p53 pseudogene: detection of a processed pseudogene using PCR. PCR Methods Applic. 1, 251-254.
50. Hulla, J. E. & Schneider, R. P. (1993). Structure of the rat p53 tumor suppressor gene. Nucl. Acids Res. 21, 713-717.
51. Hupp, T. R. & Lane, D. P. (1995). Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem. 270, 18165-18174.
52. Hupp, T. R., Meek, D. W., Midgley, C. A. & Lane, D. P. (1992). Regulation of the specific DNA binding function of p53. Cell, 71, 875-886.
53. Hupp, T. R., Meek, D. W., Midgley, C. A. & Lane, D. P. (1993). Activation of the cryptic DNA binding function of mutant forms of p53. Nucl. Acids Res. 21, 3167-3174.
54. Hupp, T. R., Sparks, A. & Lane, D. P. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell, 83, 237-245.
55. Ishioka, C., Englert, C., Winge, P., Yan, Y. X., Engelstein, M. & Friend, S. H. (1995). Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene, 10, 1485-1492.
56. Jayaraman, L. & Prives, C. (1995). Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 c-terminus. Cell, 81, 1021-1029.
57. Jeffrey, P. D., Gorina, S. & Pavletich, N. P. (1995). Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science, 267, 1498-1502.
58. Jenkins, J. R. & Stürzbecher, H. (1988). The p53 oncogene. In The Oncogene Handbook (Reddy, E. P., Skalka, A. M. & Curran, T., eds), pp. 403-423, Elsevier, Amsterdam.
59. Jenkins, J. R., Rudge, K., Redmond, S. & Wade-Evans, A. (1984). Cloning and expression analysis of full lengh mouse cDNA encoding the transformation associated protein p53. Nucl. Acids Res. 12, 5609-5626.
60. Jenkins, J. R., Chumakov, P., Addison, C., Stürzbzecher, H. W. & Wade-Evans, A. (1988). Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J. Virol. 62, 3902-3906.
61. Kao, C. C., Yew, P. R. & Berk, A. J. (1990). Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1 B 55K proteins. Virology, 179, 806-814.
62. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
63. Kay, H. D., Mountjoy, C. P., Wu, G. Q., Cornish, K. G. & Smith, L. J. (1994). Sequence of a cDNA encoding the p53 protein in rhesus monkey (Macaca mulatta). Gene, 138, 223-226.
64. Kazantsev, A. & Sancar, A. (1995). Does the p53 up-regulated gadd45 protein have a role in excision repair? Science, 270, 1003-1004.
65. Kearsey, J. M., Shivji, M. K. K., Hall, P. A. & Wood, R. D. (1995). Does the p53 up-regulated gadd45 protein have a role in excision repair? Science, 270, 1004-1005.
66. Kraegel, S. A., Pazzi, K. A. & Madewell, B. R. (1995). Sequence analysis of canine p53 in the region of exons 3-8. Cancer Letters, 92, 181-186.
67. Kuleszmartin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D. & Lee, L. (1994). Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14, 1698-1708.
68. Lam, K. T. & Calderwood, S. K. (1992). HSP70 binds specifically to a peptide derived from the highly conserved domain (I) region of p53. Biochem. Biophys. Res. Commun. 184, 167-174.
69. Lamb, P. & Crawford, L. (1986). Characterization of the human p53 gene. Mol. Cell. Biol. 6, 1379-1385.
70. Lane, D. P. & Benchimol, S. (1990). p53: oncogene or anti-oncogene? Genes Dev. 4, 1-8.
71. Lee, S., Elenbaas, B., Levine, A. & Griffith, J. (1995). p53 and its 14 kDa c-terminal domain recognize primary DNA damage in the form of insertion deletion mismatches. Cell, 81, 1013-1020.
72. Lee, W., Harveey, T. S., Yin, Y., Yau, P., Litchfield, D. & Arrowsmith, C. H. (1994). Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1, 877-890.
73. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E. & Anderson, C. W. (1992). Human DNA-activated protein kinase phosphorylates serine-15 and serine-37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12, 5041-5049.
74. Legros, Y., Lacabanne, V., D'Agay, M. F., Larsen, C. J., Pla, M. & Soussi, T. (1993). Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull. Cancer, 80, 102-110.
75. Legros, Y., Mcintyre, P. & Soussi, T. (1992). The cDNA cloning and immunological characterization of hamster p53. Gene, 112, 247-250.
76. Legros, Y., Lafon, C. & Soussi, T. (1994a). Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene, 9, 2071-2076.
77. Legros, Y., Meyer, A., Ory, K. & Soussi, T. (1994b). Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene, 9, 3689-3694.
78. Lin, J. Y., Chen, J. D., Elenbaas, B. & Levine, A. J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Gene Dev. 8, 1235-1246.
79. Liu, X., Miller, C. W., Koeffler, P. H. & Berk, A. J. (1993). The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13, 3291-3300.
80. Lozano, G. & Levine, A. J. (1991). Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol. Carcinogegen. 4, 3-9.
81. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron de Fromentel, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Leduc, A., Peyrat, J. P., Janin, N., Bressac, B. & Soussi, T. (1993). Analysis of p53 antibodies in patients with various cancers define B-Cell epitopes of human p53 - distribution on primary structure and exposure on protein surface. Cancer Res. 53, 5872-5876.
82. Marston, N. J., Crook, T. & Vousden, K. H. (1994). Interaction of p53 with MDM2 is independent of E6 and does not mediate wild-type transformation suppressor function. Oncogene, 9, 2707-2716.
83. Martin, D. W., Munoz, R. M., Subler, M. A. & Deb, S. (1993). p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268, 13062-13067.
84. Martinez, J., Georgoff, l., Martinez, J. & Levine, A. J. (1991). Cellular localization and cell cycle regulation by a temperature-sensitive p53-protein. Gene Dev. 5, 151-159.
85. Matlashewski, G., Lamb, P., Pim, D., Peacok, J., Crawford, L. & Benchimol, S. (1984). Isolation and characterization of a human p53 cDNA clone: expression of the human p53. EMBO J. 3, 3257-3262.
86. Meek, D. W. (1994). Post-translational modification of p53. Seminar Cancer Biol. 5, 203-210.
87. Meek, D. W., Simon, S., Kikkawa, U. & Eckhart, W. (1990). The p53 tumour suppressor protein is phosphorylated at serine-389 by casein kinase-II. EMBO J. 9, 3253-3260.
88. Michalovitz, D., Halevy, O. & Oren, M. (1990). Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62, 671-680.
89. Milne, D. M., Palmer, R. H., Campbell, D. G. & Meek, D. W. (1992). Phosphorylation of the p53 tumour-suppressor protein at 3 N-terminal sites by a novel casein kinase I-like enzyme. Oncogene, 7, 1361-1369.
90. Milne, D. M., Campbell, D. G., Caudwell, F. B. & Meek, D. W. (1994). Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J. Biol. Chem. 269, 9253-9260.
91. Milner, J. (1984). Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature, 310, 143-145.
92. Milner, J. (1991). A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc. Roy. Soc. Lond. 245, 139-145.
93. Milner, J. (1994). Forms and functions of p53. Seminar Cancer Biol. 5, 211-219.
94. Milner, J. (1995). Flexibility: the key to p53 function? Trends Biochem. Sci. 20, 49-51.
95. Milner, J. & McCornick, F. (1980). Lymphocyte stimulation: concanavalin A induces the expression of a 53k protein. Cell. Biol. Int. Rep. 4, 663-667.
96. Milner, J. & Medcalf, E. A. (1990). Temperature-dependent switching between wild-type and mutant forms of p53-Val135. J. Mol. Biol. 216, 481-484.
97. Milner, J. & Medcalf, E. A. (1991). Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell, 65, 765-774.
98. Milner, J., Cook, A. & Mason, J. (1990). p53 is associated with P34Cdc2 in transformed cells. EMBO J. 9, 2885-2889.
99. Miyashita, T. & Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299.
100. Molinari, M. & Milner, J. (1995). p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 e6. Oncogene, 10, 1849-1854.
101. Mosner, J., Mummenbrauer, T., Bauer, C., Sczakiel, G., Grosse, F. & Deppert, W. (1995). Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14, 4442-4449.
102. Nigro, J. M., Sikorski, R., Reed, S. I. & Vogelstein, B. (1992). Human p53 and CDC2Hs genes combine to inhibit the proliferation of saccharomyces-cerevisiae. Mol. Cell. Biol. 12, 1357-1365.
103. Okuda, M., Umeda, A., Sakai, T., Ohashi, T., Momoi, Y., Youn, H. Y., Watari, T., Goitsuka, R., Tsujimoto, H. & Hasegawa, A. (1994). Cloning of feline p53 tumor-suppressor gene and its aberration in hematopoietic tumors. Int. J. Cancer, 58, 602-607.
104. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gvuris, J., Kinzler, K. W. & Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor-p53. Nature, 362, 857-860.
105. Oren, M. & Levine, A. (1983). Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl Acad. Sci. USA, 80, 56-59.
106. Ory, K., Legros, Y., Auguin, C. & Soussi, T. (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13, 3496-3504.
107. Pavletich, N. P., Chambers, K. A. & Pabo, C. O. (1993). The DNA-binding domain of p53 contains the 4 conserved regions and the major mutation hot spots. Gene Dev. 7, 2556-2564.
108. Pennica, D., Goeddel, D. V., Hayflick, J. J., Reich, N. C., Anderson, C. W. & Levine, A. J. (1984). The amino acid sequence of murine p53 determined from a c-DNA clone. Virology, 134, 477-782.
109. Picksley, S. M., Vojtesek, B., Sparks, A. & Lane, D. P. (1994). Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene, 9, 2523-2529.
110. Pietenpol, J. A., Tokino, T., Thiagalingam, S., Eldeiry, W. S., Kinzler, K. W. & Vogelstein, B. (1994). Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl Acad. Sci. USA, 91, 1998-2002.
111. Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P. & Mann, K. (1995). Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol. 15, 3892-3903.
112. Raycroft, L., Wu, H. & Lozano, G. (1990). Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science, 249, 1049-1051.
113. Reed, M., Woelker, B., Wang, P., Wang, Y., Anderson, M. E. & Tegtmeyer, P. (1995). The c-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl Acad. Sci. USA, 92, 9455-9459.
114. Rigaudy, P. & Eckhart, W. (1989). Nucleotide sequence of a cDNA encoding the monkey cellular phosphoprotein-p53. Nucl. Acids Res. 17, 8375.
115. Rivkina, M. B., Cullen, J. M., Robinson, W. S. & Marion, P. L. (1994). State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res. 54, 5430-5437.
116. Samad, A. & Carroll, R. B. (1991). The tumor suppressor p53 is bound to RNA by a stable covalent linkage. Mol. Cell. Biol. 11, 1598-1606.
117. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F. & Soussi, T. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52, 6380-6384.
118. Schlichtholz, B., Tredaniel, J., Lubin, R., Zalcman, G., Hirsch, A. & Soussi, T. (1994). Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69, 809-816.
119. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J. & Shenk, T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 89, 12028-12032.
120. Shaulian, E., Zauberman, A., Ginsberg, D. & Oren, M. (1992). Identification of a minimal transforming domain of p53 - negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12, 5581-5592.
121. Shaulsky, G., Goldfinger, N., Benzeev, A. & Rotter, V. (1990). Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10, 6565-6577.
122. Shaw, P., Freeman, J., Bovey, R. & Iggo, R. (1996). Regulation of specific DNA binding by p53: evidence for a role for o-glycosylation and charged residues at the carboxy-terminus. Oncogene, 12, 921-930.
123. Smith, M. L., Chen, I. T., Zhan, Q. M., Bae, I. S., Chen, C. Y., Gilmer, T. M., Kastan, M. B., Oconnor, P. M. & Fornace, A. J. (1994). Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science, 266, 1376-1380.
124. Soussi, T., Caron de Fromentel, C., Méchali, M., May, P. & Kress, M. (1987). Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene, 1, 71-78.
125. Soussi, T., Bègue, A., Stehelin, D. & May, P. (1988a). Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. Nucl. Acids Res. 16, 11383.
126. Soussi, T., Caron de Fromentel, C., Breugnot, C. & May, E. (1988b). Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. Nucl. Acids Res. 16, 11384.
127. Soussi, T., Caron de Fromentel, C. & May, P. (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5, 945-952.
128. Soussi, T., Legros, Y., Lubin, R., Ory, K. & Schlichtholz, B. (1994). Multifactorial analysis of p53 alteration in human cancer - a review. Int. J. Cancer, 57, 1-9.
129. Stephen, C. W. & Lane, D. P. (1992). Mutant conformation of p53: precise epitope mapping using a filamentous phage library. J. Mol. Biol. 225, 577-583.
130. Tan, T. H., Wallis, J. & Levine, A. J. (1986). Identification of the protein p53 domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J. Virol. 59, 574-583.
131. Thut, C. J., Chen, J. L., Klemm, R. & Tjian, R. (1995). p53 transcriptional activation mediated by coactivators TAF(II)40 and TAF(II)60. Science, 267, 100-104.
132. Truant, R., Xiao, H., Ingles, C. J. & Greenblatt, J. (1993). Direct interaction between the transcriptional activation domain of human p53 and the TATA Box-binding protein. J. Biol. Chem. 268, 2284-2287.
133. Ullrich, S. J., Mercer, W. E. & Appella, E. (1992). Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene, 7, 1635-1643.
134. Ullrich, S. J., Sakaguchi, K., Leesmiller, S. P., Fiscella, M., Mercer, W. E., Anderson, C. W. & Appella, E. (1993). Phosphorylation at Ser-15 and Ser-392 in mutant p53-Molecules from human tumors is altered compared to wild-type p53. Proc. Natl Acad. Sci. USA, 90, 5954-5958.
135. Vojtesek, B., Dolezalova, H., Lauerova, L., Svitakova, M., Havlis, P., Kovarik, J., Midgley, C. A. & Lane, D. P. (1995). Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene, 10, 389-393.
136. Wagner, P., Simanis, V., Maimets, T., Keenan, E., Addison, C., Brain, R., Grimaldi, M., Sturzbecher, H. W. & Jenkins, J. (1991). A human tumour-derived mutant p53-protein induces a p34cdc2 reversible growth arrest in fission yeast. Oncogene, 6, 1539-1547.
137. Wang, P., Reed, M., Wang, Y., Mayr, G., Stenger, J. E., Anderson, M. E., Schwedes, J. F. & Tegtmeyer, P. (1994). p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14, 5182-5191.
138. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R. & Harris, C. C. (1994). Hepatitis B virus X protein inhibits p53 Sequence-Specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA, 91, 2230-2234.
139. Wang, Y. & Eckhart, W. (1992). Phosphorylation sites in the amino-terminal region of mouse p53. Proc. Natl Acad. Sci. USA, 89, 4231-4235.
140. Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Andersen, M. E., Schwedes, J. F. & Tegtmeyer, P. (1993). p53 domains - identification and characterization of 2 autonomous DNA-Binding regions. Gene Dev. 7, 2575-2586.
141. Waterman, J. L. F., Shenk, J. L. & Halazonetis, T. D. (1995). The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14, 512-519.
142. Williamson, M. P. (1994). The structure and function of proline-rich regions in proteins. Biochem. J. 297, 249-260.
143. Wu, X. W., Bayle, J. H., Olson, D. & Levine, A. J. (1993). The p53 mdm-2 autoregulatory feedback loop. Gene Dev. 7, 1126-1132.
144. Zakut-Houri, R., Oren, M., Bienz, B., Lavie, V., Hazum, S. & Givol, D. (1983). A single gene and a pseudogene for the cellular tumour antigen p53. Nature, 306, 594-597.
145. Zhang, W., Guo, X. Y., Hu, G. Y., Liu, W. B., Shay, J. W. & Deisseroth, A. B. (1994). A temperature-sensitive mutant of human p53. EMBO J. 13, 2535-2544.